Novel substituted indoloquinoxalines of formula (I
wherein
R
1
is hydrogen or represents one or more similar or different substituents in the positions 7 to 10 selected from the group halogen, lower alkyl/alkoxy, hydroxy, trifluoromethyl, trichloromethyl, trifluoromethoxy,
R
2
represents similar or different C
1
-C
4
alkyl substituents,
X is CO or CH
2
,
Y is OH, NH
2
, NH—(CH
2
)
n
—R
3
wherein R
3
represents lower alkyl, OH, NH
2
, NHR
4
or NR
5
R
6
wherein R
4
, R
5
and R
6
independently are lower alkyl or cyclo-alkyl and n is an integer of from 2 to 4,
with the provision that when X is CH
2
, Y is OH or NH—(CH
2
)
n
—OH,
and pharmacologically acceptable salts thereof are described. The compounds are useful as drugs for preventing and/or treating autoimmune diseases.
Novel substituted indoloquinoxalines of formula (I R2 (I) Y Wherein R1 is hydrogen or represents one or more similar or different substituents in the positions 7 to 10 selected from the group halogen, lower alkyl/alkoxy, hydroxy, trifluoromethyl, trichloromethyl, trifluoromethoxy, R2 represents similar or different C1-C4 alkyl substituents, X is CO or CH2, Y is OH, NH2, NH-(CH2)n-R3 wherein R3 represents lower alkyl, OH, NH2, NHR4 or NR5R6 wherein R4, R5 and R6 independently are lower alkyl or cycloalkyl and n is an integer of from 2 to 4, with the provision that when X is CH2, Y is OH or NH-(CH2)n-OH, and pharmacologically acceptable salts thereof are described. The compounds are useful as drugs for preventing and/or treating autoimmune diseases.